Non-Alcoholic Fatty Liver Disease, An Issue of Clinics in Liver Disease, 1st Edition
Author :
By Paul J. Gaglio, MD, FACP, AGAF, FAASLD
Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can prog
...view more
Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD.
Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD.
Author Information
By Paul J. Gaglio, MD, FACP, AGAF, FAASLD, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
eBooks : Built for busy schedules & tailored for your goals.
Affordable knowledge, built for you
Get the resources you need-often at a lower cost than print. Quality content designed to support your goals, without stretching your budget.
Seamless access wherever you are
Open your eBook on your laptop, tablet, or phone - online or offline. Learning fits into your life, no matter where you go.
Always in sync
Start reading on one device and pick up right where you left off on another. Your progress and notes stay with you, every step of the way.
Tools the make learning stick
Highlight key points, take notes, create flashcards, or listen to your eBook read aloud. Interactive features help you deepen your knowledge, your way.
Your eBook is ready whenever you are!
1. Check your email for your access code.
2. Sign into or create your VitalSource account and redeem your code.
The access code for your new eBook will be sent in your order confirmation email. Your code can also be accessed in your My Account section on the Elsevier webshop.
If you do not receive your code within a few minutes, please check your spam folder.
Step-by-step guidance on how to download Bookshelf and also redeem your code can be found here.
The access code for your new eBook does not expire. However, we always suggest redeeming immediately after purchase to start experiencing the benefits of and insights from your purchase. Important to note - the code provided is a single use code and only valid for the edition you purchase. It does not provide access to past nor future editions of the title.
You will have unlimited access to your eBook on the device to which it was downloaded.
Discover the various learning features that our eBooks offer on the Bookshelf® Reader! For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information on the learning functions can be found on the Vitalsource page.
Quality is our top priority. That's why we collaborate with the leading eBook reader provider VitalSource. VitalSource has its own eBook reader Bookshelf®, which you can easily download. This reader is very user-friendly and offers more features than other standard readers. For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information can be found on the Vitalsource page.
Elsevier offers its eBooks in ePub format, as we believe this format is best suited to display our content ideally on as many devices as possible.
You can return your eBook within 13 days of purchase. eBooks that have been partially printed or flipped through more than 15% are excluded from returns.
https://www.elsevierhealth.com.au/non-alcoholic-fatty-liver-disease-an-issue-of-clinics-in-liver-disease-9780323416962.html294692Non-Alcoholic Fatty Liver Disease, An Issue of Clinics in Liver Diseasehttps://www.elsevierhealth.com.au/media/catalog/product/9/7/9780323416962_9.jpg127.47169.95AUDInStock/Medicine & Surgery/Gastroenterology & Hepatology/Clinics/Medicine/Gastroenterology & Hepatology/Clinics/Clinics/Medicine/Gastroenterology & Hepatology/Product Format/Clinics/Product Format/Clinics/Product Format/Clinics4335139438872550546075054666525504152598945936812593682659368311418269243350884886536505455351451205259833593680959368235936828Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD. Due to the current obesity epidemic, non-alcoholic fatty liver disease (NAFLD) is prevalent in a significant portion of the United States patient population. It is being increasingly recognized that NAFLD affects both adults and children and can progress to end stage liver disease with resultant cirrhosis, portal hypertension, and hepatocellular carcinoma. In addition, several extrahepatic conditions may be linked to NAFLD including cardiovascular disease, insulin requiring and type 2 diabetes mellitus, obstructive sleep apnea, colonic adenomas, hyperuricemia, vitamin D deficiency, hyperferritinemia, pancreatic steatosis, hypothyroidism, and polycystic ovarian syndrome. Therapies for NAFLD are evolving rapidly. This issue will analyze patient demographics, risk factors, pathophysiology, patient presentation, and treatments for NAFLD.00add-to-cart97803234169622016ProfessionalBy Paul J. Gaglio, MD, FACP, AGAF, FAASLD20161Book152w x 229h (6.00" x 9.00")Elsevier015 Apr 2016Please allow 10-14 working days for deliveryBy <STRONG>Paul J. Gaglio</STRONG>, MD, FACP, AGAF, FAASLD, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NYClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoNoPlease SelectPlease SelectNoNoPlease Select